BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 23, 2026
Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
Musculoskeletal RSS Feed RSS

Sanofi BTK inhibitor tolebrutinib hits phase III endpoints in MS

Sep. 3, 2024
By Tamra Sami
Sanofi SA’s brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor, tolebrutinib, met the primary endpoint in the phase III Hercules trial in non-relapsing secondary progressive multiple sclerosis (nrSPMS). The first compound to show reduction in disability accumulation in MS, tolebrutinib delayed the time to onset of confirmed disability progression in people with nrSPMS, a population for which there are currently no approved therapies.
Read More
AI-generated illustration of muscular man running

ARDD 2024: Age without disease, exercise muscles and win $111M

Sep. 3, 2024
By Mar de Miguel
Aging is part of the life cycle and, although the effects are not manifest until after adulthood, it actually occurs from birth. The concept of senescence has traditionally been associated with aging. However, an embryo has senescent cells. In that case, what is aging, how can it be measured, and from what point in the life cycle?
Read More
AI-generated illustration of muscular man running
Aging

ARDD 2024: Age without disease, exercise muscles and win $111M

Sep. 3, 2024
By Mar de Miguel
Aging is part of the life cycle and, although the effects are not manifest until after adulthood, it actually occurs from birth. The concept of senescence has traditionally been associated with aging. However, an embryo has senescent cells. In that case, what is aging, how can it be measured, and from what point in the life cycle?
Read More
AI-generated illustration of muscular man running
Aging

ARDD 2024: Age without disease, exercise muscles and win $111M

Aug. 30, 2024
By Mar de Miguel
Aging is part of the life cycle and, although the effects are not manifest until after adulthood, it actually occurs from birth. The concept of senescence has traditionally been associated with aging. However, an embryo has senescent cells. In that case, what is aging, how can it be measured, and from what point in the life cycle?
Read More
Hourglass on glowing circuit board, symbolizing time and technology
Aging

ARDD 2024: Back to the future in the times of aging research

Aug. 29, 2024
By Mar de Miguel
Since the publication of The Hallmarks of Aging in 2013, aging research has exploded. The field now has more than 300,000 articles on the biological signals of the effect of time on the body. What would Marty McFly, the legendary character from the Back to the Future saga who traveled with his DeLorean time machine from the ‘80s to the ‘50s, think if he visited 2024 and saw laboratories experimenting with techniques to turn back the biological clocks of cells or increase the lifespan of rejuvenated mice?
Read More
Musculoskeletal

Mwyngil Therapeutics divulges new NLRP3 inflammasome inhibitors

Aug. 23, 2024
Mwyngil Therapeutics Inc. has synthesized compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of arthritis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), osteoporosis, hypertension, inflammation, SARS-CoV-2 infection (COVID-19), autoimmune disease and Alzheimer’s disease, among others.
Read More
Illustration showing symptoms of Sjögren’s syndrome
Musculoskeletal

Study unveils GRK2 as therapeutic target in Sjögren’s syndrome

Aug. 22, 2024
G protein-coupled receptor kinase 2 (GRK2) is a crucial kinase that has been shown to interact with multiple signaling molecules under different pathological conditions, including fibrosis.
Read More
Illustration of brain with electrical activity background
Neurology/psychiatric

Tevard’s tRNA therapies gain ground for genetic epilepsies

Aug. 14, 2024
By Karen Carey
With a move into Lilly Gateway Labs in Boston’s Seaport District, privately held Tevard Biosciences Inc. is ramping up development of its transfer RNA (tRNA)-based therapies to cure everything from Dravet syndrome and other neurological conditions to cardiology indications and muscular dystrophies.
Read More
Illustration of brain with electrical activity background
Newco news

Tevard’s tRNA therapies gain ground for genetic epilepsies

Aug. 13, 2024
By Karen Carey
With a move into Lilly Gateway Labs in Boston’s Seaport District, privately held Tevard Biosciences Inc. is ramping up development of its transfer RNA (tRNA)-based therapies to cure everything from Dravet syndrome and other neurological conditions to cardiology indications and muscular dystrophies.
Read More
Man holding raised arm with illustrated overlay of nerves
Inflammatory

COX-2 inhibitor AAT-076 ameliorates neuropathic pain

Aug. 12, 2024
AAT-076 was tested in the preclinical setting for its analgesic potential in COX-1 and COX-2 assays, as well as in in vivo rat models of air pouch inflammation, adjuvant-induced arthritis and neuropathic pain models. The compound was selected as a candidate analgesic compound due to its effective COX-2 inhibition within the central nervous system.
Read More
Previous 1 2 … 19 20 21 22 23 24 25 26 27 … 605 606 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of Alzheimer's disease in the brain

    ADPD 2026: Three inflection points to target Alzheimer’s disease

    BioWorld Science
    A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • SERCA inhibitor from Sumitomo shows promise for MSA-C treatment

    BioWorld Science
    At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing